AI agents are powerful, but without a strong control plane and hard guardrails, they’re just one bad decision away from chaos.

India is being targeted by multiple espionage campaigns delivered by the Pakistan-attributed Transparent Tribe (aka APT36).

Canopy Network has announced it is launching Canopy Templates, a new blockchain building tool designed to aid in AI-assisted development.

Master AI hackathons with this comprehensive playbook on Vibe Coding. Learn how to build winning AI hackathon apps using AI ...

So, you’re looking to get better at coding with Python, and maybe you’ve heard about LeetCode. It’s a pretty popular place to practice coding problems, especially if you’re aiming for tech jobs.

In this week’s edition of InnovationRx, we look at the biotech deal frenzy, Recursion’s incoming CEO, the infant formula botulism outbreak, and more. To get it in your inbox, subscribe here. Merck ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Among the myriad abilities that humans possess, which ones are uniquely human? Language has been a top candidate at least since Aristotle, who wrote that humanity was “the animal that has language.” ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Official support for free-threaded Python, and free-threaded improvements Python’s free-threaded build promises true parallelism for threads in Python programs by removing the Global Interpreter Lock ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...